Summary
BPC-157 is a synthetic peptide of 15 amino acids. Its sequence is derived from a protein found in human gastric juice. It has been studied mainly in animal models, with a large share of the published work coming from a single research group in Croatia, and a 2025 review written for musculoskeletal clinicians notes how widely available the compound has become relative to the evidence behind it.
What it targets
Reviews describe BPC-157 as acting through several overlapping pathways, including VEGFR2 and nitric oxide synthesis via the Akt-eNOS axis, and engaging ERK1/2 signalling, with reported effects on blood vessel formation, fibroblast activity and neuromuscular stabilisation, particularly in poorly vascularised tissue such as tendon. A 2026 systematic review screened 630 records down to 64 studies, of which 52 were preclinical and 12 were early human or observational reports, and concluded that the preclinical evidence is small in volume and varied in quality while the human data is limited to small safety-oriented reports. A laboratory study of rat tendon explants and cultured tendon cells reported increased tissue outgrowth, improved cell survival under oxidative stress and increased cell migration.
Clinical Research
Suppliers stocking BPC-157
29 of the 30 listed suppliers. Each row opens its full listing.